<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0403256975
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BUFOMIX 160/4.5MCG EASYHALER
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BUDESONIDE,FORMTEROL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        160,4.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Inhalation powder
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Inhaler
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        158.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Orion Corporation, Orion Pharma" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Orion Corporation, Orion Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03AK07 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Bufomix Easyhaler is an inhaler that is used to treat asthma in adults and adolescents aged 12 - 17 years. It is also used to treat the symptoms of Chronic Obstructive Pulmonary Disease (COPD) in adults aged 18 years and older. It contains two different medicines: budesonide and formoterol fumarate dihydrate.</p><ul><li>Budesonide belongs to a group of medicines called &lsquo;corticosteroids&rsquo;. It works by reducing and preventing swelling and inflammation in your lungs.</li><li>Formoterol fumarate dihydrate belongs to a group of medicines called &lsquo;long-acting beta 2 adrenoceptor agonists&rsquo; or &lsquo;bronchodilators&rsquo;. It works by relaxing the muscles in your airways. This helps you to breathe more easily.</li></ul><p><strong>Asthma</strong></p><p>Bufomix Easyhaler 160/4.5 can be prescribed for asthma in two different ways.</p><p><strong>a) </strong><strong>Some people are prescribed two asthma inhalers: Bufomix Easyhaler 160/4.5 and a separate &lsquo;reliever inhaler&rsquo;.</strong></p><ul><li>They use Bufomix Easyhaler every day. This helps to prevent asthma symptoms from happening.</li><li>They use their &lsquo;reliever inhaler&rsquo; when they get asthma symptoms, to make it easier to breathe again.</li></ul><p><strong>b) </strong><strong>Some people are prescribed Bufomix Easyhaler 160/4.5 as their only asthma inhaler.</strong></p><ul><li>They use Bufomix Easyhaler every day. This helps to prevent asthma symptoms from happening.</li><li>They also use Bufomix Easyhaler when they need extra doses for relief of asthma symptoms, to make it easier to breathe again and if agreed with the doctor also to prevent asthma symptoms from happening (for example, when exercising or on exposure to allergens). They do not need a separate inhaler for this.</li></ul><p><strong>Chronic obstructive pulmonary disease (COPD)</strong></p><p>Bufomix Easyhaler 160/4.5 can also be used to treat the symptoms of COPD in adults. COPD is a long-term disease of the airways in the lungs, which is often caused by cigarette smoking.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Bufomix Easyhaler</strong></p><ul><li>If you are allergic to budesonide, formoterol or to the other ingredient of this medicine (listed in section 6) which is lactose (which contains small amounts of milk protein).</li></ul><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before using Bufomix Easyhaler if you:</p><ul><li>Are diabetic</li><li>Have a lung infection</li><li>Have high blood pressure or you have ever had a heart problem (including an uneven heartbeat, a very fast pulse, narrowing of the arteries or heart failure)</li><li>Have problems with your thyroid or adrenal glands</li><li>Have low levels of potassium in your blood</li><li>Have severe liver problems.</li></ul><p>Contact your doctor if you experience blurred vision or other visual disturbances.</p><p>Rinse your mouth after inhaling your dose in order to avoid fungal infection in the mouth.</p><p><strong>Other medicines and Bufomix Easyhaler </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>Some medicines may increase the effects of Bufomix Easyhaler and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat).</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p><ul><li>Beta-blocker medicines (such as atenolol or propranolol for high blood pressure), including eyedrops (such as timolol for glaucoma).</li><li>&nbsp;Medicines for a fast or uneven heart beat (such as quinidine).</li><li>Medicines like digoxin, often used to treat heart failure.</li><li>Diuretics, also known as &lsquo;water tablets&rsquo; (such as furosemide). These are used to treat high blood pressure.</li><li>Steroid medicines that you take by mouth (such as prednisolone).</li><li>Xanthine medicines (such as theophylline or aminophylline). These are often used to treat asthma.</li><li>Other bronchodilators (such as salbutamol).</li><li>Tricyclic anti-depressants (such as amitriptyline) and the anti-depressant nefazodone.</li><li>Phenothiazine medicines (such as chlorpromazine and prochlorperazine).</li><li>Medicines to treat infections (such as ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin and telithromycin).</li><li>Medicines for Parkinson&rsquo;s disease (such as leva-dopa).</li><li>Medicines for thyroid problems (such as levo-thyroxine).</li></ul><p>If any of the above applies to you, or if you are not sure, talk to your doctor or pharmacist before using Bufomix Easyhaler.</p><p>Also tell your doctor or pharmacist if you are going to have a general anesthetic for an operation or for dental work.</p><p><strong>Pregnancy and &nbsp;breast-feeding </strong></p><ul><li>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</li><li>Do not use Bufomix Easyhaler unless your doctor tells you to.</li><li>If you get pregnant while using Bufomix Easyhaler, do not stop using Bufomix Easyhaler but talk to your doctor immediately.</li></ul><p><strong>Driving and using machines </strong></p><p>Bufomix &nbsp;Easyhaler has no or negligible effect on your ability to drive or to use tools or machines.</p><p><strong>Bufomix &nbsp;Easyhaler contains lactose </strong></p><p>Bufomix&nbsp; Easyhaler contains lactose<strong> </strong>which is a type of sugar. Each inhaled dose contains 3800 mcg lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before using this medicine. The amount of lactose in this medicine does not normally cause problems in people who are lactose intolerant.</p><p>The excipient lactose contains small amounts of milk proteins, which may cause allergic reaction.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</li><li>It is important to use Bufomix Easyhaler every day, even if you have no asthma or COPD symptoms at the time.</li><li>Your doctor will want to regularly check your asthma symptoms.</li></ul><p>If you have been taking steroid tablets for your asthma or COPD, your doctor may reduce the number of tablets that you take, once you start to use Bufomix Easyhaler. If you have been taking oral steroid tablets for a long time, your doctor may want you to have blood tests from time to time. When reducing oral steroid tablets, you may feel generally unwell even though your chest symptoms may be improving. You might experience symptoms such as a stuffy or runny nose, weakness or joint or muscle pain and rash (eczema). If any of these symptoms bother you, or if symptoms such as headache, tiredness, nausea (feeling sick) or vomiting (being sick) occur, please contact your doctor immediately. You may need to take other medication if you develop allergic or arthritic symptoms. Speak to your doctor if you are concerned as to whether you should continue to use Bufomix Easyhaler.</p><p>Your doctor may consider adding steroid tablets to your usual treatment during periods of stress (for example, when you have a chest infection or before an operation).</p><p><strong><em>Important information about your asthma or COPD symptoms</em></strong></p><p>If you feel you are getting breathless or wheezy while using Bufomix Easyhaler, you should continue to use Bufomix Easyhaler but go to see your doctor as soon as possible, as you may need additional treatment.</p><p>Contact your doctor immediately if:</p><ul><li>Your breathing is getting worse or you often wake up at night with asthma.</li><li>Your chest starts to feel tight in the morning or your chest tightness lasts longer than usual.</li></ul><p>These signs could mean that your asthma or COPD is not being properly controlled and you may need different or additional treatment immediately.<strong> </strong></p><p><strong>Asthma</strong></p><p>Bufomix Easyhaler 160/4.5 can be prescribed for asthma in two different ways. The amount of Bufomix Easyhaler to use and when to use it depends on how it has been prescribed for you.</p><p>a)&nbsp; If you have been prescribed Bufomix Easyhaler and a separate reliever inhaler, read the section called &lsquo;A) Using Bufomix Easyhaler and a separate reliever inhaler&rsquo;.</p><p>b) If you have been prescribed Bufomix Easyhaler as your only inhaler, read the section called &lsquo;B) Using Bufomix Easyhaler as your only asthma inhaler&rsquo;.</p><p><strong>a) </strong><strong>Using Bufomix Easyhaler and a separate reliever inhaler </strong></p><p>Use your Bufomix Easyhaler every day. This helps to prevent asthma symptoms from happening.</p><p><em>Adults (18 years and above)</em></p><ul><li>The usual dose is 1 or 2 inhalations, twice a day.</li><li>Your doctor may increase this to 4 inhalations, twice a day.</li><li>If your symptoms are well controlled, your doctor may ask you to take your medicine once a day.</li></ul><p><em>Adolescents (12 to 17 years)</em></p><ul><li>The usual dose is 1 or 2 inhalations, twice a day.</li><li>If your symptoms are well controlled, your doctor may ask you to take your medicine once a day.</li></ul><p>A lower strength of budesonide/ formoterol fumarate dihydrate is available for children aged from 6 to 11 years.</p><p>Budesonide/ formoterol fumarate dihydrate is not recommended to be used in children who are younger than 6 years.</p><p>Your doctor will help you to manage your asthma. They will adjust the dose of this medicine to the lowest dose that controls your asthma. However, do not adjust the dose without talking to your doctor (or asthma nurse) first.</p><p>Use your separate &lsquo;reliever inhaler&rsquo; to treat asthma symptoms when they happen.<strong> </strong>Always keep your &lsquo;reliever inhaler&rsquo; with you to use when you need it. Do not use Bufomix Easyhaler to treat asthma symptoms -</p><p>use your reliever inhaler.</p><p><strong>b) </strong><strong>Using Bufomix Easyhaler as your only asthma inhaler</strong></p><p>Only use Bufomix Easyhaler in this way if your doctor has told you to and if you are aged 12 or above.</p><p>Use your Bufomix Easyhaler 160/4.5 every day<strong>. </strong>This helps to prevent asthma symptoms from happening.</p><p>You can take:</p><ul><li>1 inhalation in the morning and 1 inhalation in the evening</li></ul><p>or</p><ul><li>2 inhalations in the morning</li></ul><p>or</p><ul><li>2 inhalations in the evening.</li></ul><p>Your doctor may increase this to 2 inhalations twice a day.</p><p>Also, use Bufomix Easyhaler 160/4.5 as a &lsquo;reliever inhaler&rsquo; to treat asthma symptoms when they happen and to prevent asthma symptoms from happening (for example, when exercising or on exposure to allergens).</p><ul><li>If you get asthma symptoms, take 1 inhalation and wait a few minutes.</li><li>If you do not feel better, take another inhalation.</li><li>Do not take more than 6 inhalations at a single time.</li></ul><p>Always keep your Bufomix Easyhaler with you, so you can use it when you need it.</p><p>A total daily dose of more than 8 inhalations is not normally needed. However, your doctor may allow you to take up to 12 inhalations a day for a limited period.</p><p>If you regularly need to use 8 or more inhalations a day, make an appointment to see your doctor or nurse. They may need to change your treatment.</p><p>Do not use more than 12 inhalations in total in 24 hours.</p><p>If you are doing exercise and you get asthma symptoms, use Bufomix Easyhaler as described here. It is important that you discuss with your doctor the use of Bufomix Easyhaler to prevent asthma symptoms from happening; how often you exercise or how often &nbsp;you are exposed to allergens could impact the treatment that it is prescribed to you.</p><p><strong>COPD (Chronic Obstructive Pulmonary Disease)</strong></p><ul><li>Only to be used by adults (aged 18 years and above).</li><li>The usual dose is 2 inhalations twice a day.</li></ul><p>Your doctor may also prescribe other bronchodilator drugs, for example anticholinergics (such as tiotropium or ipratropium bromide) for your COPD disease.<strong> </strong></p><p><strong>If you use more Bufomix Easyhaler than you should</strong></p><p>It is important that you take your dose as stated on the pharmacist&rsquo;s label or as advised by your doctor. You should not exceed your prescribed dose without seeking medical advice.</p><p>The most common symptoms that may occur after if you use more Bufomix Easyhaler 160/4.5 than you should are trembling, headache or a rapid heartbeat.</p><p><strong>If you forget to use Bufomix Easyhaler</strong></p><ul><li>If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose.</li><li>Do not take a double dose to make up for a forgotten dose.</li></ul><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p><p><strong>The instructions how to use the inhaler are at the end of the leaflet.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If either of the following happen to you, stop using Bufomix Easyhaler and talk to your doctor immediately:</strong></p><ul><li>Swelling of your face, particularly around your mouth (tongue and/or throat and/or difficulty to swallow) or hives together with difficulties to breath (angioedema) and/or sudden feeling of faintness. This may mean that you are having an allergic reaction. This happens rarely, may affect up to 1 in 1,000 people.</li><li>Sudden acute wheezing or shortness of breath immediately after using your inhaler. If either of these symptoms occur, stop using your Bufomix Easyhaler inhaler straightaway and use your &lsquo;reliever&rsquo; inhaler. Contact your doctor immediately as you may need to have your treatment changed. This happens very rarely, may affect up to 1 in 10,000 people.</li></ul><p><strong>Tell your doctor if you have any of the following while taking Bufomix Easyhaler, they could be symptoms of a lung infection:</strong></p><ul><li>Fever or chills</li><li>Increased mucus production, change in mucus colour</li><li>Increased cough or increased breathing difficulties.</li></ul><p>Pneumonia (infection of the lung) in COPD patients is a common side effect (may affect up to 1 in 10 people).</p><p><strong><em>Other possible side effects</em></strong><strong>:</strong></p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>Palpitations (awareness of your heart beating), trembling or shaking. If these effects occur, they are usually mild and usually disappear as you continue to use Bufomix Easyhaler.</li><li>Thrush (a fungal infection) in the mouth. This is less likely if you rinse your mouth out with water after using your Bufomix Easyhaler.</li><li>Mild sore throat, coughing and a hoarse voice.</li><li>Headache.</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Feeling restless, nervous or agitated.</li><li>Disturbed sleep.</li><li>Feeling dizzy.</li><li>Nausea (feeling sick).</li><li>Fast heart beat.</li><li>Bruising of the skin.</li><li>Muscle cramps.</li><li>Blurred vision.</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><ul><li>Rash, itching.</li><li>Bronchospasm (tightening of the muscles in the airways which causes wheezing). If the wheezing comes on suddenly after using Bufomix Easyhaler stop using Bufomix Easyhaler and talk to your doctor immediately.</li><li>Low levels of potassium in your blood.</li><li>Uneven heart beat.</li></ul><p><strong>Very rare (may affect up to 1 in 10,000 people)</strong></p><ul><li>Depression.</li><li>Changes in behaviour, especially in children.</li><li>Chest pain or tightness in the chest (angina pectoris).</li><li>An increase in the amount of sugar (glucose) in your blood.</li><li>Taste changes, such as an unpleasant taste in the mouth.</li><li>Changes in your blood pressure.</li></ul><p><strong>Inhaled corticosteroids can affect the normal production of steroid hormones in your body, particularly if you use high doses for a long time. The effects include: </strong></p><ul><li>Changes in bone mineral density (thinning of the bones)</li><li>Cataract (clouding of the lens in the eye)</li><li>Glaucoma (increased pressure in the eye)</li><li>A slowing of the rate of growth of children and adolescents</li><li>An effect on the adrenal gland (a small gland next to the kidney).</li></ul><p>These effects are much less likely to happen with inhaled corticosteroids than with corticosteroid tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Before and after opening: Do not store above 30ᵒC.</p><p>Store in the original package in order to protect from moisture.</p><p>After opening, it is required to keep the Easyhaler in its protective cover.</p><p>If your Bufomix Easyhaler gets damp you need to replace it with a new one.</p><p>Replace Bufomix Easyhaler 4 months after you opened the laminate bag.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are budesonide and formoterol fumarate dihydrate. Each inhaled dose contains 160 micrograms budesonide and 4.5 micrograms formoterol fumarate dihydrate.</p><p>The other ingredient is lactose monohydrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Bufomix Easyhaler 160 mcg/4.5 mcg Inhalation Powder is a white to yellowish powder in a metered inhaler which has a white body with red upper part and is packed in a laminate bag with a protective cover.

Pack size: 120 Inhaled doses.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder </strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer and Under licensed from </strong></p><p>Orion Corporation, Orion Pharma</p><p>Orionintie 1</p><p>FI-02200 Espoo</p><p>Finland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 04/2021; version number SA3.1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">بوفوميكس إيزي هيلر هو جهاز استنشاق يُستخدم لعلاج الربو عند البالغين والمراهقين الذين تتراوح أعمارهم من 12 إلى 17 عامًا. كما يُستخدم أيضًا لعلاج أعراض مرض الانسداد الرئوي المزمن لدى البالغين في عمر 18 عامًا فما فوق. يحتوي بوفوميكس إيزي هيلر على دوائين مختلفين: بوديزونيد وفيوماريت الفورموتيرول ثنائي الماء.</p><ul dir="rtl"><li>ينتمي بوديزونيد إلى مجموعة الأدوية التي تُسمى &rsquo;الستيرويدات القشرية&lsquo;. ويعمل الدواء من خلال الحد من تورم والتهاب الرئتين ومنعهما.</li><li>ينتمي فيوماريت الفورموتيرول ثنائي الماء إلى مجموعة الأدوية التي تُسمى &rsquo;ناهضات مستقبلات بيتا 2 الأدرينالية طويلة المفعول&lsquo; أو &rsquo;موسعات القصبات&lsquo;. ويعمل هذا الدواء من خلال إرخاء عضلات المسالك الهوائية. يساعدك ذلك على التنفس بسهولة أكبر.</li></ul><p dir="RTL"><strong>الربو </strong></p><p dir="RTL">يمكن وصف بوفوميكس إيزي هيلر 160/4.5 لعلاج الربو بطريقتين مختلفتين.</p><p dir="RTL"><strong>أ&zwnj;)&nbsp;&nbsp; </strong><strong>يتم وصف جهازي استنشاق للربو لبعض الأشخاص: </strong><strong>بوفوميكس إيزي هيلر 160/4.5 و&rsquo;جهاز استنشاق مخفف للأعراض&lsquo; منفصل. </strong></p><ul dir="rtl"><li>يستخدمون بوفوميكس إيزي هيلر يومياً. هذا يساعد على منع حدوث أعراض الربو.</li><li>يستخدمون &rsquo;جهاز استنشاق مخفف للأعراض&lsquo; عندما يتعرضون لأعراض الربو، لتسهيل التنفس مرة أخرى.&nbsp; &nbsp;</li></ul><p dir="RTL"><strong>ب&zwnj;)</strong><strong>يتم وصف </strong><strong>بوفوميكس إيزي هيلر 160/4.5 لبعض الأشخاص كجهاز الاستنشاق الوحيد للربو لديهم. </strong></p><ul dir="rtl"><li>يستخدمون بوفوميكس إيزي هيلر يومياً. هذا يساعد على منع حدوث أعراض الربو.</li><li>يستخدمون أيضاً بوفوميكس إيزي هيلر عندما يحتاجون إلى جرعات إضافية لتخفيف أعراض الربو، لتسهبل التنفس مرة أخرى وفي حال تم الاتفاق مع الطبيب أيضاً على منع حدوث أعراض الربو (على سبيل المثال، عند ممارسة التمارين أو عند التعرض لمسببات الحساسية). لا يحتاجون إلى جهاز استنشاق منفصل لذلك.&nbsp;</li></ul><p dir="RTL"><strong>مرض الانسداد الرئوي المزمن </strong></p><p dir="RTL">يمكن استخدام بوفوميكس إيزي هيلر 160/4.5 أيضاً لعلاج أعراض مرض الانسداد الرئوي المزمن لدى البالغين. مرض الانسداد الرئوي المزمن هو مرض طويل الأمد يصيب المسالك الهوائية في الرئتين، والذي يسببه عادة تدخين السجائر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم بوفوميكس إيزي هيلر</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لبوديزونيد، فورموتيرول أو لأي من مكونات هذا الدواء الأخرى (المذكورة في القسم 6) المتمثلة في اللاكتوز (الذي يحتوي على كميات صغيرة من بروتين الحليب).</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل استخدام بوفوميكس إيزي هيلر إذا كنت:</p><ul dir="rtl"><li>مصاب بمرض السكري</li><li>تعاني من عدوى رئوية</li><li>تعاني من ارتفاع ضغط الدم أو عانيت في أي وقت مضى من مشاكل في القلب (بما في ذلك عدم انتظام ضربات القلب، أو تسارع النبضات، أو ضيق الشرايين أو فشل القلب)</li><li>تعاني من مشاكل في الغدة الدرقية أو الغدة الكظرية</li><li>تعاني من انخفاض مستويات البوتاسيوم في الدم</li><li>تعاني من مشاكل شديدة في الكبد.</li></ul><p dir="RTL">اتصل بطبيبك &nbsp;إذا عانيت من تغيّم الرؤية أو اضطرابات بصرية أخرى.&nbsp;</p><p dir="RTL">قم بمضمضة فمك بعد استنشاق جرعتك لتجنب حدوث العدوى الفطرية في الفم.</p><p dir="RTL"><strong>الأدوية الأخرى وبوفوميكس إيزي هيلر</strong><strong> </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أخذت مؤخراً أو قد تأخذ أية أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">قد تتسبب بعض الأدوية في زيادة آثار بوفوميكس إيزي هيلر، وقد يرغب طبيبك في مراقبتك بعناية إذا كنت تتناول هذه الأدوية (وتشمل بعض أدوية علاج فيروس العوز المناعي البشري: ريتونافير، كوبيسيستات)</p><p dir="RTL">أبلغ الطبيب أو الصيدلي إذا كنت تتناول أيّ من الأدوية التالية على وجه الخصوص:</p><ul dir="rtl"><li>أدوية حاصرات مستقبلات بيتا، (مثل أتينولول أو بروبرانولول لعلاج ضغط الدم المرتفع)، وتشمل قطرات العيون (مثل تيمولول لعلاج الزرق).</li><li>أدوية لعلاج سرعة نبضات القلب أو عدم انتظامها (مثل كينيدين).</li><li>أدوية مثل ديجوكسين، الذي يُستخدم غالبًا لعلاج فشل القلب.</li><li>مدرات البول، و المعروفة أيضاً بـ &rsquo;أقراص الماء&lsquo; (مثل فوروسيميد). وتُستخدم هذه الأدوية لعلاج ارتفاع ضغط الدم.</li><li>الأدوية الستيرويدية التي تتناولها عن طريق الفم (مثل بريدنيزولون).</li><li>أدوية زانثين (مثل تيوفيلين أو أمينوفيلين). وتُستخدم هذه الأدوية غالبًا لعلاج الربو.</li><li>موسعات الشعب الهوائية الأخرى (مثل سالبوتامول).</li><li>مضادات الاكتئاب ثلاثية الحلقات (مثل أميتربتيلين) ومضاد الاكتئاب نيفازودون.</li><li>أدوية فينوثيازين (مثل كلوربرومازين وبروكلوربيرازين).</li><li>أدوية علاج العدوى (مثل كيتوكونازول، وإيتراكونازول، وفوريكونازول، وبوساكونازول، وكلاريثروميسين وتيليثرومايسين).</li><li>أدوية لعلاج مرض باركنسون (مثل ليفودوبا).</li><li>أدوية لعلاج مشاكل الغدة الدرقية (مثل ليفوثيروكسين).</li></ul><p dir="RTL">إذا كان ينطبق عليك أي مما سبق أو إذا لم تكن متأكدًا، فاستشر طبيبك أو الصيدلي قبل استخدام بوفوميكس إيزي هيلر.</p><p dir="RTL">أخبر طبيبك أو الصيدلي أيضًا إذا كنت ستخضع لتخدير عام لإجراء عملية جراحية أو لعلاج الأسنان.</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong></p><ul dir="rtl"><li>يرجى استشارة طبيبك أو الصيدلي قبل استخدام هذا الدواء إذا كنتِ حاملاً أو مرضعًا، أو تعتقدين بأنك حاملاً أو تخططين لذلك.</li><li>لا تستخدمي بوفوميكس إيزي هيلر إلا إذا أخبركِ الطبيب بذلك.</li><li>إذا أصبحتِ حاملاً وأنت تستخدمين بوفوميكس إيزي هيلر، فلا تتوقفي عن استخدام بوفوميكس إيزي هيلر ولكن تحدثي إلى الطبيب على الفور.</li></ul><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">لا يوجد أثر لبوفوميكس إيزي هيلر أو يوجد له تأثير ضئيل على قدرتك على القيادة أو استخدام الأدوات أو الآلات.</p><p dir="RTL"><strong>يحتوي بوفوميكس إيزي هيلر على اللاكتوز</strong></p><p dir="RTL">يحتوي بوفوميكس إيزي هيلر على اللاكتوز<strong> </strong>وهو أحد أنواع السكر. تحتوي كل نشقة على 3800 مكغم لاكتوز أحادي الماء. إذا كان الطبيب قد أخبرك بأنك لا تتحمل بعض السكريات، فتحدث معه قبل استخدام هذا الدواء. في المعتاد، لا تسبب كمية اللاكتوز الموجودة في هذا الدواء مشكلات لدى الأشخاص الذين لا يتحملون اللاكتوز.</p><p dir="RTL">يحتوي سواغ اللاكتوز على كميات صغيرة من بروتين الحليب، الذي قد يسبب رد فعل تحسسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>قم دائمًا باستخدام دوائك تمامًا كما أخبرك طبيبك. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكداً.</li><li>من المهم استخدام بوفوميكس إيزي هيلر يوميًا، حتى إذا لم تكن تعاني من أعراض الربو أو مرض الانسداد الرئوي المزمن في ذلك الوقت.</li><li>سيرغب طبيبك بالقيام بالفحص المنتظم لأعراض الربو لديك. &nbsp;</li></ul><p dir="RTL">إذا كنت تتناول أقراص ستيرويدية لعلاج الربو أو مرض الانسداد الرئوي المزمن، فإن طبيبك قد يقلل عدد الأقراص التي تتناولها بمجرد أن تبدأ باستخدام بوفوميكس إيزي هيلر. إذا كنت تتناول أقراص ستيرويدية فموية لوقت طويل، فإنه قد يطلب طبيبك منك إجراء اختبارات دم من وقت لآخر. قد تشعر بالمرض بشكل عام عند تقليل عدد الأقراص الستيرويدية الفموية التي تتناولها، حتى بالرغم من تحسن أعراض الصدر لديك. قد تتعرض لأعراض مثل احتقان الأنف أو سيلان الأنف، الضعف أو آلام في العضلات أو المفاصل والطفح (الإكزيما). يرجى الاتصال بالطبيب على الفور، في حال كانت أي من هذه الأعراض تزعجك، أو إذا ظهرت أعراض مثل الصداع، الإرهاق، الغثيان أو القيء. قد يتوجب عليك تناول أدوية أخرى إذا تعرضت لأعراض حساسية أو التهاب المفاصل. تحدث مع طبيبك إذا كنت قلقًا بشأن ضرورة الاستمرار في استخدام أو وقف بوفوميكس إيزي هيلر.</p><p dir="RTL">قد يأخذ الطبيب في عين الاعتبار إضافة أقراص ستيرويدية لعلاجك المعتاد خلال فترات التوتر (على سبيل المثال، عندما تعاني من عدوى صدرية أو قبل إجراء عملية جراحية).</p><p dir="RTL"><strong><em>معلومات مهمة حول أعراض الربو أو مرض الانسداد الرئوي المزمن</em></strong></p><p dir="RTL">إذا شعرت بعسر التنفس أو صفير عند التنفس أثناء تناول بوفوميكس إيزي هيلر، فيجب عليك الاستمرار في تناول بوفوميكس إيزي هيلر ولكن يتوجب عليك زيارة طبيبك بأسرع ما يُمكن حيث إنك قد تكون بحاجة إلى علاج إضافي.</p><p dir="RTL">اتصل بطبيبك على الفور إذا:</p><ul dir="rtl"><li>تدهور التنفس لديك أو أنك تستيقظ كثيرًا خلال الليل بسبب الربو.</li><li>بدء الشعور بضيق في الصدر في الصباح أو استمرار ضيق الصدر لديك أكثر من المعتاد.</li></ul><p dir="RTL">قد تعني هذه العلامات عدم السيطرة على الربو أو مرض الانسداد الرئوي المزمن بشكل كامل وقد تكون بحاجة إلى علاج مختلف أو علاج إضافي بشكل فوري.<strong> </strong></p><p dir="RTL"><strong>الربو</strong></p><p dir="RTL">&nbsp;يمكن أن يوصف بوفوميكس إيزي هيلر 160/4.5 لعلاج الربو من خلال طريقتين مختلفتين. الكمية المستخدمة من بوفوميكس إيزي هيلر وكيفية استخدامها تعتمد على كيفية وصفها لك.</p><p dir="RTL">أ) إذا تم وصف بوفوميكس إيزي هيلر مع جهاز الاستنشاق المخفف &nbsp;للأعراض المنفصل، قم بقراءة قسم يسمى &rsquo;أ) استخدام بوفوميكس إيزي هيلر مع جهاز الاستنشاق المخفف للأعراض المنفصل&lsquo;.</p><p dir="RTL">ب) إذا تم وصف بوفوميكس إيزي هيلر كجهاز الاستنشاق الوحيد، قم بقراءة قسم يسمى &rsquo;ب) استخدام بوفوميكس إيزي هيلر كجهاز الاستنشاق الوحيد للربو لديك&lsquo;.</p><p dir="RTL"><strong>أ) استخدام </strong><strong>بوفوميكس</strong><strong> </strong><strong>إيزي هيلر مع جهاز الاستنشاق</strong><strong> </strong><strong>ال</strong><strong>مخفف للأعراض ال</strong><strong>منفصل</strong></p><p dir="RTL">استخدم بوفوميكس إيزي هيلر يوميًا. يساعدك ذلك على منع حدوث أعراض الربو.</p><p dir="RTL"><em>البالغون</em><em> (18 </em><em>عامًا</em><em> </em><em>فأكثر</em><em>)</em></p><ul dir="rtl"><li>الجرعة المعتادة هي نشقة واحدة أو اثنتين، مرتين في اليوم.</li><li>يُمكن لطبيبك زيادة الجرعة لتصل إلى 4 نشقات، مرتين في اليوم.</li><li>إذا تم السيطرة على الأعراض تمامًا، فقد يطلب طبيبك منك تناول الدواء مرة واحدة في اليوم.</li></ul><p dir="RTL"><em>المراهقون</em><em> (12 </em><em>إلى</em><em> 17 </em><em>عامًا</em><em>)</em></p><ul dir="rtl"><li>الجرعة المعتادة هي نشقة واحدة أو نشقتين، مرتين في اليوم.</li><li>إذا تم السيطرة على الأعراض تمامًا، فقد يطلب طبيبك منك تناول الدواء مرة واحدة في اليوم.</li></ul><p dir="RTL">يوجد تركيز أقل من بوديزونيد/فيوماريت الفورموتيرول ثنائي الماء متوفر للأطفال من عمر 6 إلى 11 عاماً.</p><p dir="RTL">لا يوصى باستخدام بوديزونيد/فيوماريت الفورموتيرول ثنائي الماء لدى الأطفال بعمر أقل من 6 أعوام.</p><p dir="RTL">سيساعدك طبيبك في التعامل مع الربو. سيقومون بتعديل جرعة الدواء إلى أقل جرعة يُمكنها التحكم بالربو. ومع ذلك، لا تقم بتعديل الجرعة بدون التحدث مع الطبيب أولاً.</p><p dir="RTL">استعمل &rsquo;جهاز الاستنشاق المخفف للأعراض&lsquo; منفصل الخاص بك لعلاج أعراض الربو عند حدوثها.<strong> </strong>احتفظ بـ &rsquo;جهاز الاستنشاق المخفف للأعراض&lsquo; معك لتستخدمه عندما تحتاج إليه. لا تستخدم بوفوميكس إيزي هيلر لعلاج أعراض الربو- استخدم جهاز الاستنشاق المخفف للأعراض.</p><p dir="RTL"><strong>ب</strong><strong>) </strong><strong>استخدام بوفوميكس</strong><strong> </strong><strong>إيزي هيلر كجهاز الاستنشاق الوحيد للربو لديك</strong></p><p dir="RTL">قم باستخدام بوفوميكس إيزي هيلر بهذه الطريقة فقط إذا أخبرك طبيبك بذلك وإذا كان عمرك 12 عام أو أكثر.</p><p dir="RTL">قم باستخدام بوفوميكس إيزي هيلر160/4.5 يوميًا. سوف يساعدك ذلك على منع حدوث أعراض الربو.</p><p dir="RTL">يمكنك أخذ:</p><ul dir="rtl"><li>نشقة واحدة في الصباح ونشقة واحدة في المساء</li></ul><p dir="RTL">أو</p><ul dir="rtl"><li>نشقتين في الصباح</li></ul><p dir="RTL">أو</p><ul dir="rtl"><li>نشقتين في المساء.</li></ul><p dir="RTL">يمكن أن يقوم طبيبك بزيادة الجرعة لنشقتين مرتين يومياً.</p><p dir="RTL">أيضاً، يستخدم بوفوميكس إيزي هيلر 160/4.5 كـ &rsquo;جهاز الاستنشاق المخفف للأعراض&lsquo; &nbsp;لعلاج أعراض الربو عند حدوثها ولمنع حدوث أعراض الربو (على سبيل المثال، عند ممارسة التمارين أو عند التعرض لمسببات الحساسية).</p><ul dir="rtl"><li>إذا أصبت بأعراض الربو، قم بأخذ نشقة واحدة ثم انتظر لعدة دقائق.</li><li>إذا لم تشعر بتحسن، قم بأخذ نشقة أخرى.</li><li>لا تقم بأخذ أكثر من 6 نشقات في المرة الواحدة.</li></ul><p dir="RTL">قم بالاحتفاظ ببوفوميكس إيزي هيلر معك دائماً، بحيث تقوم باستخدامه عند حاجتك إليه.</p><p dir="RTL">الجرعة اليومية الكلية لأكثر من 8 نشقات يومياً تعد في العادة غير لازمة. مع ذلك، يمكن أن يسمح لك طبيبك بأخذ حتى 12 نشقة في اليوم لمدة محددة.</p><p dir="RTL">إذا كنت تحتاج بالعادة إلى 8 نشقات أو أكثر في اليوم، قم بتحديد موعد لرؤية طبيبك أو الممرض. من الممكن أن يكونوا بحاجة لتغيير علاجك.</p><p dir="RTL">لا تقم باستخدام أكثر من 12 نشقة بالمجموع خلال 24 ساعة.</p><p dir="RTL">إذا كنت تمارس التمارين وأصبت بأعراض الربو، قم باستخدام بوفوميكس إيزي هيلر كما تم وصفه هنا. من المهم أن تتناقش مع طبيبك حول استخدام بوفوميكس إيزي هيلر لمنع حدوث أعراض الربو؛ عدد مرات ممارستك للتمارين أو عدد مرات تعرضتك لمسببات الحساسية يمكن أن تؤثر على علاجك الموصوف لك. &nbsp;أأينيس</p><p dir="RTL"><strong>مرض</strong><strong> </strong><strong>الانسداد</strong><strong> </strong><strong>الرئوي</strong><strong> </strong><strong>المزمن</strong></p><ul dir="rtl"><li>يستخدم لدى البالغين فقط (الذين تبلغ أعمارهم 18 عامًا فما فوق).</li><li>تبلغ الجرعة المعتادة نشقتين، مرتين في اليوم.</li></ul><p dir="RTL">قد يصف طبيبك أيضًا أدوية أخرى موسعة للقصبات مثل، مضادات الفعل الكوليني (مثل تيوتروبيوم أو إبراتروبيوم بروميد) لعلاج مرض الانسداد الرئوي المزمن.<strong> </strong><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا استخدمت بوفوميكس إيزي هيلر أكثر من اللازم</strong></p><p dir="RTL">من المهم أن تتناول الجرعة الموصوفة في ملصق الصيدلي أو كما أوصى بها الطبيب. يجب ألا تتجاوز الجرعة الموصوفة لك دون طلب الاستشارة الطبية.</p><p dir="RTL">الأعراض الأكثر شيوعًا والتي قد تحدث إثر تعاطي جرعة زائدة من بوفوميكس إيزي هيلر 160/4.5 هي الارتجاف، الصداع أو سرعة ضربات القلب.</p><p dir="RTL"><strong>إذا نسيت استخدام بوفوميكس إيزي هيلر</strong></p><ul dir="rtl"><li>في حالة نسيانك تناول الجرعة، تناولها فور تذكرها. مع ذلك، إذا تذكرتها قرب موعد الجرعة التالية، فتجاهل الجرعة الفائتة.</li><li>لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</li></ul><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا المنتج، يرجى استشارة الطبيب أو الصيدلي.</p><p><strong>تعليمات كيفية استخدام جهاز الاستنشاق موجودة في نهاية النشرة. </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong>إذا حدث أي من التالي لك، توقف عن استخدام بوفوميكس إيزي هيلر واستشر طبيبك على الفور</strong><strong>:</strong></p><ul dir="rtl"><li>تورم في وجهك، وبالتحديد حول الفم (اللسان و/أو الحلق و/أو صعوبة أثناء البلع) أو الشرى مع وجود صعوبة في التنفس (الوذمة الوعائية) و/أو شعور مفاجئ بالإغماء. قد يعني هذا أنه لديك رد فعل تحسَسي. نادراً ما يحدث هذا، وقد يؤثر على ما يصل إلى شخص واحد من كل 1000 شخص.</li><li>صفير حاد مفاجئ أو ضيق في التنفس فورا بعد استخدام جهاز الاستنشاق. إذا ظهرت أي من هذه الأعراض، فتوقف عن استخدام جهاز استنشاق بوفوميكس إيزي هيلر واستخدم جهاز الاستنشاق المخفف للأعراض فورا. تواصل مع طبيبك على الفور حيث قد تكون بحاجة إلى تغيير الدواء. نادراً جدًا، ما يحدث هذا وقد يؤثر على ما يصل إلى شخص واحد من كل 10,000 شخص.</li></ul><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك في حال شعرت بأي من الآتي إثر استخدام بوفوميكس إيزي هيلر، قد يدل ذلك على أعراض عدوى رئوية</strong><strong>:</strong></p><ul dir="rtl"><li>الحمى أو القشعريرة</li><li>زيادة كمية اخراج المخاط، تغير في لون المخاط</li><li>زيادة في السعال أو زيادة في صعوبة التنفس.</li></ul><p dir="RTL">يعد الالتهاب الرئوي (عدوى في الرئة) لدى مرضى الانسداد الرئوي المزمن من الآثار الجانبية الشائعة (قد يؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص).</p><p dir="RTL"><strong><em>الآثار الجانبية المحتملة الأخرى</em></strong><strong><em>:</em></strong></p><p dir="RTL"><strong>شائعة </strong><strong>(</strong><strong>قد تصيب ما يصل إلى شخص واحد من بين كل </strong><strong>10 </strong><strong>أشخاص</strong><strong>)</strong></p><ul dir="rtl"><li>الخفقان (الشعور بنبضات القلب)، الارتجاف أو الارتعاش. وإذا حدثت هذه الآثار، فإنها عادة ما تكون طفيفة وتختفي عادة بمجرد الاستمرار في استخدام بوفوميكس إيزي هيلر.</li><li>القُلاع (عدوى فطرية) في الفم. وتكون أقل احتمالاً عندما تمضمض فمك بالماء بعد استخدام بوفوميكس إيزي هيلر.</li><li>ألم طفيف في الحلق، السعال والصوت المبحوح.</li><li>الصداع.</li></ul><p dir="RTL"><strong>غير شائعة </strong><strong>(</strong><strong>قد تصيب ما يصل إلى شخص واحد من بين كل </strong><strong>100 </strong><strong>شخص</strong><strong>)</strong></p><ul dir="rtl"><li>الشعور بالتململ، العصبية أو الاهتياج.</li><li>اضطراب النوم.</li><li>الشعور بالدوخة.</li><li>الغثيان.</li><li>تسارع نبضات القلب.</li><li>تكدم الجلد.</li><li>تشنجات العضلات.</li><li>تغيّم الرؤية.</li></ul><p dir="RTL"><strong>نادرة </strong><strong>(</strong><strong>قد تصيب ما يصل إلى شخص واحد من بين كل </strong><strong>1000 </strong><strong>شخص</strong><strong>)</strong></p><ul dir="rtl"><li>الطفح، الحكة.</li><li>تشنجات في القصبات الهوائية (انقباض العضلات في المسالك الهوائية مما يسبب الصفير). إذا حدث الصفير بشكل مفاجئ بعد استخدام بوفوميكس إيزي هيلر توقف عن استخدام بوفوميكس إيزي هيلر وتحدث مع طبيبك على الفور.</li><li>انخفاض مستويات البوتاسيوم في الدم</li><li>عدم انتظام ضربات القلب.</li></ul><p dir="RTL"><strong>نادرة للغاية </strong><strong>(</strong><strong>قد تصيب ما يصل إلى شخص واحد من بين كل </strong><strong>10000 </strong><strong>شخص</strong><strong>)</strong></p><ul dir="rtl"><li>الاكتئاب.</li><li>تغيرات في السلوك، خاصةً بين الأطفال.</li><li>ألم في الصدر أو ضيق في الصدر (الذبحة الصدرية).</li><li>زيادة في كمية السكر (الجلوكوز) في دمك.</li><li>حدوث تغيرات في المذاق، مثل الإحساس بمذاق كريه في الفم.</li><li>حدوث تغيرات في ضغط الدم.</li></ul><p dir="RTL"><strong>يمكن أن تؤثر الستيرويدات القشرية التي يتم استنشاقها على الإنتاج الطبيعي للهرمونات الستيرويدية في جسمك، خاصةً إذا استخدمت جرعات كبيرة لمدة طويلة</strong><strong>. </strong><strong>تشمل الآثار على</strong><strong>: &nbsp;</strong></p><ul dir="rtl"><li>حدوث تغيرات في كثافة المعادن في العظام (ترقق العظام)</li><li>الإصابة بالساد (ضبابية عدسة العين)</li><li>الإصابة بالزرق (ارتفاع الضغط في العين)</li><li>بطؤ معدل نمو الأطفال والمراهقين</li><li>تأثر الغدة الكظرية (وهي غدة صغيرة توجد بجانب الكلية).</li></ul><p dir="RTL">تحدث هذه الآثار بشكل أقل بكثير مع الستيرويدات القشرية المستنشقة مقارنة بتلك التي تؤخذ على شكل أقراص عن طريق الفم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">قبل وبعد الفتح: لا يحفظ عند درجة حرارة أعلى من 30˚ مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">بعد الفتح، يجب الإحتفاظ بالإيزي هيلر داخل غطائه الواقي.</p><p dir="RTL">إذا تعرض بوفوميكس إيزي هيلر للرطوبة فعليك استبداله بواحد جديد.</p><p dir="RTL">استبدل بوفوميكس إيزي هيلر بعد أربعة أشهر من فتح الكيس المُقوى.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &ldquo;EXP&rdquo;. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p>لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي بوديزونيد وفيوماريت الفورموتيرول ثنائي الماء. تحتوي كل نشقة على 160 ميكروغرام بوديزونيد و4,5 ميكروغرام فيوماريت الفورموتيرول ثنائي الماء.</p><p dir="RTL">المادة الأخرى المستخدمة في التركيبة التصنيعية هي لاكتوز أحادي الماء.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">بوفوميكس إيزي هيلر 160 مكغم/4.5 مكغم مسحوق للاستنشاق هو مسحوق لونه أبيض مائل إلى الصفرة معبأ في جهاز للاستنشاق به عداد جرعات، لون جسمه أبيض ولون الجزء العلوي منه أحمر ومعبأ في كيس مُقوى مع غطاء واقي.</p><p style="text-align:justify">حجم العبوة: 120 نشقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم</strong><strong> </strong><strong>وعنوان</strong><strong> </strong><strong>مالك</strong><strong> </strong><strong>رخصة</strong><strong> </strong><strong>التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com<u> </u></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة</strong><strong> </strong><strong>المصنعة</strong><strong> </strong><strong>وبترخيص من </strong></p><p dir="RTL">شركة أوريون، أوريون الدوائية</p><p dir="RTL">أوريونينتي 1</p><p dir="RTL">FI-02200 إسبو</p><p dir="RTL">فنلندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 04/2021، رقم النسخة SA3.1.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bufomix Easyhaler® 160 mcg/4.5 mcg Inhalation Powder
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each inhaled dose contains 160 micrograms budesonide and 4.5 micrograms formoterol fumarate dihydrate.

Excipient with known effect: 3800 micrograms lactose monohydrate per delivered dose.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inhalation powder in a device metered inhaler (Easyhaler).

White to yellowish powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Asthma</strong></p><p>Bufomix Easyhaler is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting &beta;<sub>2</sub>-adrenoceptor agonist) is appropriate:</p><ul><li>Patients not adequately controlled with inhaled corticosteroids and &ldquo;as needed&rdquo; inhaled short-acting &beta;<sub>2</sub>-adrenoceptor agonists.</li></ul><p>or</p><ul><li>Patients already adequately controlled on both inhaled corticosteroids and long-acting &beta;<sub>2</sub>-adrenoceptor agonists.</li></ul><p><strong>Chronic Obstructive Pulmonary Disease (COPD)</strong></p><p>Bufomix Easyhaler is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) &lt; 70% predicted normal (postbronchodilator) and an exacerbation history despite regular bronchodilator therapy (see also section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Posology</em></strong></p><p><strong>Asthma</strong></p><p>Bufomix Easyhaler is not intended for the initial management of asthma. The dosage of the components of Bufomix Easyhaler is individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with combination products is initiated but also when the maintenance dose is adjusted. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of &beta;<sub>2</sub>-adrenoceptor agonists and/or corticosteroids by individual inhalers should be prescribed.</p><p>The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Patients should be regularly reassessed by their prescriber/healthcare provider so that the dosage of Bufomix Easyhaler remains optimal. When long-term control of symptoms is maintained with the lowest recommended dosage, then the next step could include a test of inhaled corticosteroid alone.</p><p>For Bufomix Easyhaler there are two treatment approaches:</p><p><strong>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>maintenance therapy: </strong>Bufomix Easyhaler is taken as regular maintenance treatment with a separate rapid-acting bronchodilator as rescue.</p><p><strong>B. maintenance and reliever therapy: </strong>Bufomix Easyhaler is taken as regular maintenance treatment and as needed in response to symptoms.</p><p><u>A. maintenance therapy</u></p><p>Patients should be advised to have their separate rapid-acting bronchodilator available for rescue use at all times.</p><p><em>Recommended doses:</em></p><p><em>Adults (18 years and older): </em>1-2 inhalations twice daily. Some patients may require up to a maximum of 4 inhalations twice daily.</p><p><em>Adolescents (12-17 years): </em>1-2 inhalations twice daily.</p><p>In usual practice when control of symptoms is achieved with the twice daily regimen, titration to the lowest effective dose could include Bufomix Easyhaler given once daily, when in the opinion of the prescriber, a long-acting bronchodilator in combination with an inhaled corticosteroid would be required to maintain control.</p><p>Increasing use of a separate rapid-acting bronchodilator indicates a worsening of the underlying</p><p>condition and warrants a reassessment of the asthma therapy.</p><p><em>Children (6 years and older): </em>A lower strength of budesonide/ formoterol fumarate dihydrate (80 micrograms/4.5 micrograms/inhalation) is available for children 6-11 years.</p><p><em>Children under 6 years: </em>As only limited data are available, budesonide/ formoterol fumarate dihydrate is not recommended for children younger than 6 years.</p><p><u>B. maintenance and reliever therapy</u></p><p>Patients take a daily maintenance dose of Bufomix Easyhaler and in addition take Bufomix Easyhaler as needed in response to symptoms. Patients should be advised to always have Bufomix Easyhaler available for rescue use.</p><p>For patients taking Bufomix Easyhaler as reliever, preventative use of Bufomix Easyhaler for allergen- or exercise-induced bronchoconstriction should be discussed between physician and patient; the recommended use should take into consideration the frequency of need. In case of frequent need of bronchodilation without corresponding need for an increased dose of inhaled corticosteroids, an alternative reliever should be used.</p><p>Maintenance and reliever therapy should especially be considered for patients with:</p><ul><li>Inadequate asthma control and in frequent need of reliever medication</li><li>Asthma exacerbations in the past requiring medical intervention</li></ul><p>Close monitoring for dose-related adverse effects is needed in patients who frequently take high numbers of Bufomix Easyhaler as-needed inhalations.</p><p><em>Recommended doses:</em></p><p><em>Adults and adolescents (12 years and older): </em>The recommended maintenance dose is 2 inhalations per day, given either as one inhalation in the morning and evening or as 2 inhalations in either the morning or evening. For some patients a maintenance dose of 2 inhalations twice daily may be appropriate. Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion.</p><p>A total daily dose of more than 8 inhalations is not normally needed; however, a total daily dose of up to 12 inhalations could be used for a limited period. Patients using more than 8 inhalations daily should be strongly recommended to seek medical advice. They should be reassessed and their maintenance therapy should be reconsidered.</p><p><em>Children under 12 years: </em>maintenance and reliever therapy is not recommended for children.</p><p>For dosages which cannot be achieved with Bufomix Easyhaler, other strengths of budesonide/formoterol medicinal products are available.</p><p><strong>COPD</strong></p><p><em>Recommended doses:</em></p><p><em>Adults: </em>2 inhalations twice daily.</p><p><strong>General information</strong></p><p><em>Special patient groups:</em></p><p>There are no special dosing requirements for elderly patients. There are no data available for use of Bufomix Easyhaler in patients with hepatic or renal impairment. As budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver cirrhosis.</p><p><strong><em>Method of administration</em></strong></p><p>For inhalation use.</p><p><em>Instructions for correct use of Bufomix Easyhaler:</em></p><p>The inhaler is inspiratory flow-driven, which means that when the patient inhales through the mouthpiece, the substance will follow the inspired air into the airways.</p><p>&nbsp;</p><p>Note<em>: </em>It is important to instruct the patient</p><ul><li>To carefully read the instructions for use in the patient information leaflet which is packed together with each Bufomix Easyhaler.</li><li>To shake and actuate the inhaler prior to each inhalation.</li><li>To breathe in forcefully and deeply through the mouthpiece to ensure that an optimal dose is delivered to the lungs.</li><li>Never to breathe out through the mouthpiece as this will result in a reduction in the delivered dose. Should this happen the patient is instructed to tap the mouthpiece onto a table top or the palm of a hand to empty the powder, and then to repeat the dosing procedure.</li><li>Never to actuate the device more than once without inhalation of the powder. Should this happen the patient is instructed to tap the mouthpiece onto a table top or the palm of a hand to empty the powder, and then to repeat the dosing procedure.</li><li>To always replace the dust cap (and, if in use, close the protective cover) after use to prevent accidental actuation of the device (which could result in either overdosing or under dosing the patient when subsequently used).</li><li>To rinse the mouth out with water after inhaling the maintenance dose to minimise the risk of oropharyngeal thrush. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations.</li><li>To clean the mouthpiece with a dry cloth at regular intervals. Water should never be used for cleaning because the powder is sensitive to moisture.</li><li>To replace Bufomix Easyhaler when the counter reaches zero even though powder can still be observed within the inhaler.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to the excipient listed in section 6.1 (lactose, which contains small amounts of milk protein).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>It is recommended that the dose is tapered when the treatment is discontinued and should not be stopped abruptly. Complete withdrawal of inhaled corticosteroids should not be considered unless it is temporarily required to confirm diagnosis of asthma.</p><p>&nbsp;</p><p>If patients find the treatment ineffective, or exceed the highest recommended dose of Bufomix Easyhaler, medical attention must be sought (see section 4.2). Sudden and progressive deterioration in control of asthma or COPD is potentially life threatening and the patient should undergo urgent medical assessment. In this situation, consideration should be given to the need for increased therapy with corticosteroids, e.g. a course of oral corticosteroids, or antibiotic treatment if an infection is present.</p><p>&nbsp;</p><p>Patients should be advised to have their rescue inhaler available at all times, either Bufomix Easyhaler (for asthma patients using Bufomix Easyhaler as maintenance and reliever therapy) or a separate rapid-acting bronchodilator (for all patients using Bufomix Easyhaler as maintenance therapy only).</p><p>&nbsp;</p><p>Patients should be reminded to take their Bufomix Easyhaler maintenance dose as prescribed, even when asymptomatic.</p><p>&nbsp;</p><p>Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of Bufomix Easyhaler. Regular review of patients as treatment is stepped down is important. The lowest effective dose of Bufomix Easyhaler should be used (see section 4.2).</p><p>&nbsp;</p><p>Patients should not be initiated on Bufomix Easyhaler during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma.</p><p>&nbsp;</p><p>Serious asthma-related adverse events and exacerbations may occur during treatment with Bufomix Easyhaler.</p><p>&nbsp;</p><p>Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation of Bufomix Easyhaler.</p><p>&nbsp;</p><p>There are no clinical study data on budesonide/formoterol combination products available in COPD patients with a pre-bronchodilator FEV1 &gt;50% predicted normal and with a post-bronchodilator FEV1 &lt;70% predicted normal (see section 5.1).</p><p>&nbsp;</p><p>As with other inhalation therapy, paradoxical bronchospasm may occur, with an immediate increase in wheezing and shortness of breath after dosing. If the patient experiences paradoxical bronchospasm Bufomix Easyhaler should be discontinued immediately, the patient should be assessed and an alternative therapy instituted, if necessary. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightaway (see section 4.8).</p><p>&nbsp;</p><p>Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. These effects are much less likely to occur with inhalation treatment than with oral corticosteroids.</p><p>&nbsp;</p><p>Possible systemic effects include Cushing&rsquo;s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma, and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children) (see section 4.8).</p><p>&nbsp;</p><p>Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.</p><p>&nbsp;</p><p>Potential effects on bone density should be considered, particularly in patients on high doses for prolonged periods that have coexisting risk factors for osteoporosis. Long-term studies with inhaled budesonide in children at mean daily doses of 400 micrograms (metered dose) or in adults at daily doses of 800 micrograms (metered dose) have not shown any significant effects on bone mineral density. No information regarding the effect at higher doses is available.</p><p>&nbsp;</p><p>If there is any reason to suppose that adrenal function is impaired from previous systemic steroid therapy, care should be taken when transferring patients to Bufomix Easyhaler therapy.</p><p>&nbsp;</p><p>The benefits of inhaled budesonide therapy would normally minimise the need for oral steroids, but patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. Recovery may take a considerable amount of time after cessation of oral steroid therapy and hence oral steroid-dependent patients transferred to inhaled budesonide may remain at risk from impaired adrenal function for some considerable time. In such circumstances HPA axis function should be monitored regularly.</p><p>&nbsp;</p><p>Prolonged treatment with high doses of inhaled corticosteroids, particularly higher than recommended doses, may also result in clinically significant adrenal suppression. Therefore additional systemic corticosteroid cover should be considered during periods of stress such as severe infections or elective surgery. Rapid reduction in the dose of steroids can induce acute adrenal crisis. Symptoms and signs which might be seen in acute adrenal crisis may be somewhat vague but may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, decreased level of consciousness, seizures, hypotension and hypoglycaemia.</p><p>&nbsp;</p><p>Treatment with supplementary systemic steroids or inhaled budesonide should not be stopped abruptly.</p><p>&nbsp;</p><p>During transfer from oral therapy to Bufomix Easyhaler a generally lower systemic steroid action will be experienced which may result in the appearance of allergic or arthritic symptoms such as rhinitis, eczema and muscle and joint pain. Specific treatment should be initiated for these conditions. A general insufficient glucocorticosteroid effect should be suspected if, in rare cases, symptoms such as tiredness, headache, nausea and vomiting should occur. In these cases a temporary increase in the dose of oral glucocorticosteroids is sometimes necessary.</p><p>&nbsp;</p><p>To minimise the risk of oropharyngeal candida infection (see section 4.8), the patient should be instructed to rinse their mouth out with water after inhaling the maintenance dose. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations.</p><p>&nbsp;</p><p>Concomitant treatment with itraconazole, ritonavir or other potent CYP3A inhibitors should be avoided (see section 4.5). If this is not possible the time interval between administration of the interacting drugs should be as long as possible. In patients using potent CYP3A inhibitors, maintenance and reliever therapy approach is not recommended.</p><p>&nbsp;</p><p>Bufomix Easyhaler should be administered with caution in patients with thyrotoxicosis, phaeochromocytoma, diabetes mellitus, untreated hypokalaemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm or other severe cardiovascular disorders, such as ischaemic heart disease, tachyarrhythmias or severe heart failure.</p><p>&nbsp;</p><p>Caution should be observed when treating patients with prolongation of the QTc-interval. Formoterol itself may induce prolongation of the QTc-interval.</p><p>&nbsp;</p><p>The need for, and dose of inhaled corticosteroids should be re-evaluated in patients with active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways.</p><p>&nbsp;</p><p>Potentially serious hypokalaemia may result from high doses of &beta;<sub>2</sub>-adrenoceptor agonists. Concomitant treatment of &beta;<sub>2</sub>-adrenoceptor agonists with drugs which can induce hypokalaemia or potentiate a hypokalaemic effect, e.g. xanthine-derivatives, steroids and diuretics, may add to a possible hypokalaemic effect of the &beta;<sub>2</sub>-adrenoceptor agonist. Particular caution is recommended in unstable asthma with variable use of rescue bronchodilators, in acute severe asthma as the associated risk may be augmented by hypoxia and in other conditions when the likelihood for hypokalaemia is increased. It is recommended that serum potassium levels are monitored during these circumstances.</p><p>&nbsp;</p><p>As for all &beta;<sub>2</sub>-adrenoceptor agonists, additional blood glucose controls should be considered in diabetic patients.</p><p>&nbsp;</p><p><u>Pneumonia in patients with COPD</u></p><p>An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids. There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies.</p><p>&nbsp;</p><p>There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk among inhaled corticosteroid products.</p><p>&nbsp;</p><p>Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations.</p><p>&nbsp;</p><p>Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index (BMI) and severe COPD.</p><p>&nbsp;</p><p>Bufomix Easyhaler contains approx. 4 mg of lactose per inhalation. This amount does not normally cause problems in lactose intolerant people. The excipient lactose contains small amounts of milk proteins, which may cause allergic reactions.</p><p><u>&nbsp;</u></p><p><u>Paediatric populations</u></p><p>It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be re-evaluated with the aim of reducing the dose of inhaled corticosteroid to the lowest dose at which effective control of asthma is maintained, if possible.</p><p>&nbsp;</p><p>The benefits of the corticosteroid therapy and the possible risks of growth suppression must be carefully weighed. In addition consideration should be given to referring the patient to a paediatric respiratory specialist.</p><p>&nbsp;</p><p>Limited data from long-term studies suggest that most children and adolescents treated with inhaled budesonide will ultimately achieve their adult target height. However, an initial small but transient reduction in growth (approximately 1 cm) has been observed. This generally occurs within the first year of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacokinetic interactions</u></p><p>Potent inhibitors of CYP3A (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, cobicistat and HIV protease inhibitors) are likely to markedly increase plasma levels of budesonide and concomitant use should be avoided. If this is not possible the time interval between administration of the inhibitor and budesonide should be as long as possible (see section 4.4). In patients using potent CYP3A inhibitors, maintenance and reliever therapy is not recommended.</p><p>The potent CYP3A4 inhibitor ketoconazole, 200 mg once daily, increased plasma levels of concomitantly orally administered budesonide (single dose of 3 mg) on average six-fold. When ketoconazole was administered 12 hours after budesonide the concentration was on average increased only three-fold showing that separation of the administration times can reduce the increase in plasma levels. Limited data about this interaction for high-dose inhaled budesonide indicates that marked increases in plasma levels (on average four fold) may occur if itraconazole, 200 mg once daily, is administered concomitantly with inhaled budesonide (single dose of 1000 &mu;g).</p><p>Co-treatment with cobicistat-containing products is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.</p><p><u>Pharmacodynamic interactions</u></p><p>Beta-adrenergic blockers can weaken or inhibit the effect of formoterol. Bufomix Easyhaler should therefore not be given together with beta-adrenergic blockers (including eye drops) unless there are compelling reasons.</p><p>Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine) and tricyclic antidepressants can prolong the QTc-interval and increase the risk of ventricular arrhythmias.</p><p>In addition L-Dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards &beta;<sub>2</sub></p><p>sympathomimetics</p><p>Concomitant treatment with monoamine oxidase inhibitors including agents with similar properties such as furazolidone and procarbazine may precipitate hypertensive reactions.</p><p>There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.</p><p>Concomitant use of other beta-adrenergic drugs or anticholinergic drugs can have a potentially additive bronchodilating effect.</p><p>Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides.</p><p>Hypokalaemia may result from beta2-agonist therapy and may be potentiated by concomitant</p><p>treatment with xanthine derivatives, corticosteroids and diuretics (see section 4.4).</p><p>Budesonide and formoterol have not been observed to interact with any other drugs used in the treatment of asthma.</p><p><em>Paediatric populations</em></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>For Bufomix Easyhaler or the concomitant treatment with formoterol and budesonide, no clinical data on exposed pregnancies are available. Data from an embryo-fetal development study in the rat showed no evidence of any additional effect from the combination.</p><p>There are no adequate data from use of formoterol in pregnant women. In animal studies formoterol has caused adverse effects in reproduction studies at very high systemic exposure levels (see section 5.3).</p><p>Data on approximately 2000 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide. In animal studies glucocorticosteroids have been shown to induce malformations (see section 5.3). This is not likely to be relevant for humans given recommended doses.</p><p>Animal studies have also identified an involvement of excess prenatal glucocorticoids in increased risks for intrauterine growth retardation, adult cardiovascular disease and permanent changes in glucocorticoid receptor density, neurotransmitter turnover and behaviour at exposures below the teratogenic dose range.</p><p>During pregnancy, Bufomix Easyhaler should only be used when the benefits outweigh the potential risks. The lowest effective dose of budesonide needed to maintain adequate asthma control should be used.</p><p><u>Breast-feeding</u></p><p>Budesonide is excreted in breast milk. However, at therapeutic doses no effects on the suckling child are anticipated. It is not known whether formoterol passes into human breast milk. In rats, small amounts of formoterol have been detected in maternal milk. Administration of Bufomix Easyhaler to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.</p><p><u>Fertility</u></p><p>There is no data available on the potential effect of budesonide on fertility. Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bufomix Easyhaler has no or negligible influence on the ability to drive and use machines.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since Bufomix Easyhaler contains both budesonide and formoterol, the same pattern of undesirable effects as reported for these substances may occur. No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds. The most common drug related adverse reactions are pharmacologically predictable side-effects of &beta;2 agonist therapy, such as tremor and palpitations. These tend to be mild and usually disappear within a few days of treatment.</p><p>Adverse reactions, which have been associated with budesonide or formoterol, are given below, listed by system organ class and frequency. Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1 000 to &lt; 1/100), rare (&ge; 1/10 000 to &lt; 1/1 000) and very rare (&lt; 1/10 000).&nbsp;&nbsp;</p><p><strong>Table 1</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:853px"><tbody><tr><td style="vertical-align:top; width:224px"><p><strong>SOC </strong></p></td><td style="vertical-align:top; width:79px"><p><strong>Frequency </strong></p></td><td style="vertical-align:top; width:540px"><p><strong>Adverse Drug Reaction </strong></p></td></tr><tr><td style="vertical-align:top; width:224px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:79px"><p>Common</p></td><td style="vertical-align:top; width:540px"><p>Candida infections in the oropharynx, pneumonia (in COPD patients)</p></td></tr><tr><td style="vertical-align:top; width:224px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:79px"><p>Rare</p></td><td style="vertical-align:top; width:540px"><p>Immediate and delayed hypersensitivity reactions, e.g. exanthema, urticaria, pruritus, dermatitis, angioedema and anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top; width:224px"><p>Endocrine disorders</p></td><td style="vertical-align:top; width:79px"><p>Very rare</p></td><td style="vertical-align:top; width:540px"><p>Cushing&rsquo;s syndrome, adrenal suppression, growth retardation, decrease in bone mineral density</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:224px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:79px"><p>Rare</p></td><td style="vertical-align:top; width:540px"><p>Hypokalaemia</p></td></tr><tr><td style="vertical-align:top; width:79px"><p>Very rare</p></td><td style="vertical-align:top; width:540px"><p>Hyperglycaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:224px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:79px"><p>Uncommon</p></td><td style="vertical-align:top; width:540px"><p>Aggression, psychomotor hyperactivity, anxiety, sleep disorders</p></td></tr><tr><td style="vertical-align:top; width:79px"><p>Very rare</p></td><td style="vertical-align:top; width:540px"><p>Depression, behavioural changes (predominantly in children)</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:224px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:79px"><p>Common</p></td><td style="vertical-align:top; width:540px"><p>Headache, tremor</p></td></tr><tr><td style="vertical-align:top; width:79px"><p>Uncommon</p></td><td style="vertical-align:top; width:540px"><p>Dizziness</p></td></tr><tr><td style="vertical-align:top; width:79px"><p>Very rare</p></td><td style="vertical-align:top; width:540px"><p>Taste disturbances</p></td></tr><tr><td style="vertical-align:top; width:224px"><p>Eye disorders</p></td><td style="vertical-align:top; width:79px"><p>Very rare</p></td><td style="vertical-align:top; width:540px"><p>Cataract and glaucoma</p></td></tr><tr><td rowspan="4" style="vertical-align:top; width:224px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:79px"><p>Common</p></td><td style="vertical-align:top; width:540px"><p>Palpitations</p></td></tr><tr><td style="vertical-align:top; width:79px"><p>Uncommon</p></td><td style="vertical-align:top; width:540px"><p>Tachycardia</p></td></tr><tr><td style="vertical-align:top; width:79px"><p>Rare</p></td><td style="vertical-align:top; width:540px"><p>Cardiac arrhythmias, e.g. atrial fibrillation, supraventricular tachycardia, extrasystoles</p></td></tr><tr><td style="vertical-align:top; width:79px"><p>Very rare</p></td><td style="vertical-align:top; width:540px"><p>Angina pectoris. Prolongation of QTc- interval</p></td></tr><tr><td style="vertical-align:top; width:224px"><p>Vascular disorders</p></td><td style="vertical-align:top; width:79px"><p>Very rare</p></td><td style="vertical-align:top; width:540px"><p>Variations in blood pressure</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:224px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:79px"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top; width:540px"><p>Mild irritation in the throat, coughing, hoarseness</p></td></tr><tr><td style="vertical-align:top; width:79px"><p>Rare</p></td><td style="vertical-align:top; width:540px"><p>Bronchospasm</p></td></tr><tr><td style="vertical-align:top; width:224px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:79px"><p>Uncommon</p></td><td style="vertical-align:top; width:540px"><p>Nausea</p></td></tr><tr><td style="vertical-align:top; width:224px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:79px"><p>Uncommon</p></td><td style="vertical-align:top; width:540px"><p>Bruises</p></td></tr><tr><td style="vertical-align:top; width:224px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:79px"><p>Uncommon</p></td><td style="vertical-align:top; width:540px"><p>Muscle cramps</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Candida infection in the oropharynx is due to drug deposition. Advising the patient to rinse the mouth out with water after each maintenance dose will minimise the risk. Oropharyngeal Candida infection usually responds to topical anti-fungal treatment without the need to discontinue the inhaled corticosteroid. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations.</p><p>As with other inhalation therapy, paradoxical bronchospasm may occur very rarely, affecting less than 1 in 10,000 people, with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightaway. Bufomix Easyhaler should be discontinued immediately, the patient should be assessed and an alternative therapy instituted if necessary (see section 4.4).</p><p>Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing&rsquo;s Syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. Increased susceptibility to infections and impairment of the ability to adapt to stress may also occur. Effects are probably dependent on dose, exposure time, concomitant and previous steroid exposure and individual sensitivity.&nbsp;</p><p>Treatment with &beta;2 agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.</p><p><u>Paediatric populations</u><br />It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored (see section 4.4).</p><p><u>Reporting of suspected adverse reactions</u><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An overdose of formoterol would likely lead to effects that are typical for &beta;2-adrenoceptor agonists: tremor, headache, palpitations. Symptoms reported from isolated cases are tachycardia, hyperglycaemia, hypokalaemia, prolonged QTc-interval, arrhythmia, nausea and vomiting. Supportive and symptomatic treatment may be indicated. A dose of 90 micrograms administered during three hours in patients with acute bronchial obstruction raised no safety concerns.</p><p>Acute overdosage with budesonide, even in excessive doses, is not expected to be a clinical problem. When used chronically in excessive doses, systemic glucocorticosteroid effects, such as hypercorticism and adrenal suppression, may appear.</p><p>If Bufomix Easyhaler therapy has to be withdrawn due to overdose of the formoterol component of the drug, provision of appropriate inhaled corticosteroid therapy must be considered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for obstructive airway diseases: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics.</p><p>ATC-code: R03AK07</p><p><u>Mechanisms of action and Pharmacodynamic effects</u></p><p>Bufomix Easyhaler contains formoterol and budesonide, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations. The specific properties of budesonide and formoterol allow the combination to be used either as maintenance and reliever therapy or as maintenance treatment of asthma.</p><p><em>Budesonide</em></p><p>Budesonide is a glucocorticosteroid which when inhaled has a dose-dependent anti-inflammatory action in the airways, resulting in reduced symptoms and fewer asthma exacerbations. Inhaled budesonide has less severe adverse effects than systemic corticosteroids. The exact mechanism responsible for the anti-inflammatory effect of glucocorticosteroids is unknown.</p><p><em>Formoterol</em></p><p>Formoterol is a selective &beta;<sub>2</sub>-adrenoceptor adrenergic agonist that when inhaled results in rapid and longacting relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect is dose-dependant, with an onset of effect within 1-3 minutes. The duration of effect is at least 12 hours after a single dose.</p><p><u>Clinical efficacy and safety</u></p><p><strong>Asthma</strong></p><p><em>Clinical efficacy for budesonide/formoterol maintenance therapy</em></p><p>Clinical studies in adults have shown that the addition of formoterol to budesonide improved asthma symptoms and lung function, and reduced exacerbations. In two 12-week studies the effect on lung function of budesonide/formoterol was equal to that of the free combination of budesonide and formoterol, and exceeded that of budesonide alone. All treatment arms used a short-acting &beta;<sub>2</sub>-adrenoceptor agonist as needed. There was no sign of attenuation of the anti-asthmatic effect over time.</p><p>Two 12-week paediatric studies have been performed in which 265 children aged 6&ndash;11 years were treated with a maintenance dose of budesonide/formoterol (2 inhalations of 80 micrograms/4.5 micrograms/inhalation twice daily), and a short acting &beta;<sub>2</sub>-adrenoceptor agonist as needed. In both studies, lung function was improved and the treatment was well tolerated compared to the corresponding dose of budesonide alone.</p><p><em>Clinical efficacy for budesonide/formoterol maintenance and reliever therapy</em></p><p>A total of 12076 asthma patients were included in 5 double-blind efficacy and safety studies (4447 were randomised to budesonide/formoterol maintenance and reliever therapy) for 6 or 12 months. Patients were required to be symptomatic despite use of inhaled glucocorticosteroids.</p><p>Budesonide/formoterol maintenance and reliever therapy provided statistically significant and clinically meaningful reductions in severe exacerbations for all comparisons in all 5 studies. This included a comparison with budesonide/formoterol at a higher maintenance dose with terbutaline as reliever (study 735) and budesonide/formoterol at the same maintenance dose with either formoterol or terbutaline as reliever (study 734) (Table 2). In Study 735, lung function, symptom control, and reliever use were similar in all treatment groups. In Study 734, symptoms and reliever use were reduced and lung function improved, compared with both comparator treatments. In the 5 studies combined, patients receiving budesonide/formoterol maintenance and reliever therapy used, on average, no reliever inhalations on 57% of treatment days. There was no sign of development of tolerance over time.</p><p>Table 2 Overview of severe exacerbations in clinical studies</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td style="vertical-align:top"><p>Study No. Duration</p></td><td style="vertical-align:top"><p>Treatment groups</p></td><td style="vertical-align:top"><p>n</p></td><td colspan="2" style="vertical-align:top"><p>Severe exacerbations<strong>a </strong>Events&nbsp;&nbsp;&nbsp; Events/</p><p>patient-year</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Study 735</strong></p><p><strong>6 months</strong></p></td><td style="vertical-align:top"><p><strong>Budesonide/formoterol 160/4.5 &micro;g bd + as</strong></p><p><strong>needed</strong></p></td><td style="vertical-align:top"><p><strong>1103</strong></p></td><td style="vertical-align:top"><p><strong>125</strong></p></td><td style="vertical-align:top"><p><strong>0.23</strong><sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Budesonide/formoterol 320/9 &micro;g bd + terbutaline</p><p>0.4 mg as needed</p></td><td style="vertical-align:top"><p>1099</p></td><td style="vertical-align:top"><p>173</p></td><td style="vertical-align:top"><p>0.32</p></td></tr><tr><td style="vertical-align:top"><p>Salmeterol/fluticasone 2 x 25/125 &micro;g bd +</p><p>terbutaline 0.4 mg as needed</p></td><td style="vertical-align:top"><p>1119</p></td><td style="vertical-align:top"><p>208</p></td><td style="vertical-align:top"><p>0.38</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Study 734</strong></p><p><strong>12 months</strong></p></td><td style="vertical-align:top"><p><strong>Budesonide/formoterol 160/4.5 &micro;g bd + as</strong></p><p><strong>needed</strong></p></td><td style="vertical-align:top"><p><strong>1107</strong></p></td><td style="vertical-align:top"><p><strong>194</strong></p></td><td style="vertical-align:top"><p><strong>0.19</strong><sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Budesonide/formoterol </strong>160/4.5 &micro;g bd +</p><p>formoterol 4.5 &micro;g as needed</p></td><td style="vertical-align:top"><p>1137</p></td><td style="vertical-align:top"><p>296</p></td><td style="vertical-align:top"><p>0.29</p></td></tr><tr><td style="vertical-align:top"><p><strong>Budesonide/formoterol </strong>160/4.5 &micro;g bd +</p><p>terbutaline 0.4 mg as needed</p></td><td style="vertical-align:top"><p>1138</p></td><td style="vertical-align:top"><p>377</p></td><td style="vertical-align:top"><p>0.37</p></td></tr></tbody></table></td></tr></tbody></table><p><sup>a</sup> Hospitalisation/emergency room treatment or treatment with oral steroids</p><p><sup>b</sup> Reduction in exacerbation rate is statistically significant (P-value &lt;0.01) for both comparisons</p><p>Comparable efficacy and safety in adolescents and adults was demonstrated in 6 double-blind studies, comprising the 5 studies mentioned above and an additional study using a higher maintenance dose of 160/4.5 micrograms, two inhalations twice daily. These assessments were based on a total of 14385 asthma patients of whom 1847 were adolescents. The number of adolescent patients taking more than 8 inhalations on at least one day as part of budesonide/formoterol maintenance and reliever therapy was limited, and such use was infrequent.</p><p>In 2 other studies with patients seeking medical attention due to acute asthma symptoms, budesonide/formoterol provided rapid and effective relief of bronchoconstriction similar to salbutamol and formoterol.</p><p><strong>COPD</strong></p><p>In two 12-month studies, the effect on lung function and the rate of exacerbation (defined as courses of oral steroids and/or course of antibiotics and/or hospitalisations) in patients with moderate to severe COPD was evaluated. The inclusion criteria for both studies was pre-bronchodilator FEV1 &lt;50% predicted normal.</p><p>Median post-bronchodilator FEV1 at inclusion in the trials was 42% predicted normal. The mean number of exacerbations per year (as defined above) was significantly reduced with budesonide/formoterol as compared with treatment with formoterol alone or placebo (mean rate 1.4 compared with 1.8-1.9 in the placebo/formoterol group). The mean number of days on oral corticosteroids/patient during the 12 months was slightly reduced in the budesonide/formoterol group (7-8 days/patient/year compared with 11-12 and 9-12 days in the placebo and formoterol groups, respectively). For changes in lung-function parameters, such as FEV1, budesonide/formoterol was not superior to treatment with formoterol alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Bufomix Easyhaler and budesonide/formoterol turbuhaler fixed-dose combination of budesonide and formoterol have been shown to be bioequivalent with regard to total systemic exposure and exposure via the lungs.</p><p>Budesonide/formoterol turbuhaler fixed-dose combination of budesonide and formoterol, and the corresponding monoproducts have been shown to be bioequivalent with regard to systemic exposure of budesonide and formoterol, respectively. In spite of this, a small increase in cortisol suppression was seen after administration of the fixed-dose combination compared to the monoproducts. The difference is considered not to have an impact on clinical safety.</p><p>There was no evidence of pharmacokinetic interactions between budesonide and formoterol.</p><p>Pharmacokinetic parameters for the respective substances were comparable after the administration of budesonide and formoterol as monoproducts or as the fixed-dose combination. For budesonide, AUC was slightly higher, rate of absorption more rapid and maximal plasma concentration higher after administration of the fixed combination. For formoterol, maximal plasma concentration was similar after administration of the fixed combination. Inhaled budesonide is rapidly absorbed and the maximum plasma concentration is</p><p>reached within 30 minutes after inhalation. In studies, mean lung deposition of budesonide after inhalation via the powder inhaler ranged from 32% to 44% of the delivered dose. The systemic bioavailability is approximately 49% of the delivered dose. In children 6-16 years of age the lung deposition falls in the same range as in adults for the same given dose. The resulting plasma concentrations were not determined.</p><p>Inhaled formoterol is rapidly absorbed and the maximum plasma concentration is reached within 10 minutes after inhalation. In studies the mean lung deposition of formoterol after inhalation via the powder inhaler ranged from 28% to 49% of the delivered dose. The systemic bioavailability is about 61% of the delivered dose.</p><p><u>Distribution and biotransformation </u></p><p>Plasma protein binding is approximately 50% for formoterol and 90% for budesonide. Volume of</p><p>distribution is about 4 l/kg for formoterol and 3 l/kg for budesonide. Formoterol is inactivated via conjugation reactions (active O-demethylated and deformylated metabolites are formed, but they are seen mainly as inactivated conjugates). Budesonide undergoes an extensive degree (approximately 90%) of biotransformation on first passage through the liver to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6-beta-hydroxy-budesonide and 16-alfa-hydroxy-prednisolone, is less than 1% of that of budesonide. There are no indications of any metabolic interactions or any displacement reactions between formoterol and budesonide.</p><p><u>Elimination</u></p><p>The major part of a dose of formoterol is transformed by liver metabolism followed by renal elimination.</p><p>After inhalation, 8% to 13% of the delivered dose of formoterol is excreted unmetabolised in the urine.</p><p>Formoterol has a high systemic clearance (approximately 1.4 l/min) and the terminal elimination half-life averages 17 hours.</p><p>Budesonide is eliminated via metabolism mainly catalysed by the enzyme CYP3A4. The metabolites of budesonide are eliminated in urine as such or in conjugated form. Only negligible amounts of unchanged budesonide have been detected in the urine. Budesonide has a high systemic clearance (approximately 1.2 l/min) and the plasma elimination half-life after i.v. dosing averages 4 hours.</p><p>The pharmacokinetics of budesonide or formoterol in children and patients with renal failure are unknown. The exposure of budesonide and formoterol may be increased in patients with liver disease.</p><p><u>Linearity/non-linearity</u></p><p>Systemic exposure for both budesonide and formoterol correlates in a linear fashion to administered dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxicity observed in animal studies with budesonide and formoterol, given in combination or separately, were effects associated with exaggerated pharmacological activity.</p><p>In animal reproduction studies, corticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results do not seem to be relevant in humans at the recommended doses. Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure and implantation losses as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use. However, these animal experimental results do not seem to be relevant in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Lactose monohydrate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                As packaged for sale: 24 months.

After first opening the laminate bag: 4 months. Do not store above 30°C. Store in the original package in order to protect from moisture.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30ᵒC. Store in the original package in order to protect from moisture.</p><p>After opening, it is required to keep the Easyhaler in its protective cover.</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metered inhaler which has a white body with red upper part and is packed in a laminate bag with a protective cover.</p><p>Pack size: 120 inhaled doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                25 April 2021 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>